key: cord-1032144-lufywkco
authors: Fung,, Monica; Babik, Jennifer M
title: COVID-19 in Immunocompromised Hosts: What We Know So Far
date: 2020-06-27
journal: Clin Infect Dis
DOI: 10.1093/cid/ciaa863
sha: ccfadff9b920c6f44545adfa5abb37fa4ba50305
doc_id: 1032144
cord_uid: lufywkco

The coronavirus disease 2019 (COVID-19) pandemic caused by SARS coronavirus 2 (SARS-CoV-2) has caused significant morbidity and mortality for patients and stressed healthcare systems worldwide. The clinical features and outcomes of COVID-19 among immunosuppressed patients, who are at presumed risk for more severe disease but who may also have decreased detrimental inflammatory responses, are not well characterized. We review the existing literature on COVID-19 among immunocompromised populations ranging from cancer patients and solid organ transplant recipients to patients with HIV and those receiving immunomodulatory therapy for autoimmune disease. Patients with malignancy and solid organ transplant recipients may be at increased risk of severe COVID-19 disease and death whereas for those with other types of immunocompromise, current evidence is less clear. Overall, further prospective, controlled studies are needed to determine the attributable risk of immunocompromising conditions and therapies on COVID-19 disease prognosis.

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has led to a global pandemic with over 8 million reported cases and 400,000 deaths. 1, 2 Due to impaired immune defenses from both underlying disease and treatment, immunocompromised patients with respiratory virus infection are at risk for more severe infection and increased rates of bacterial and fungal superinfection compared to their immunocompetent counterparts. 3, 4 Similar concerns exist in regards to immunosuppressed patients infected with SARS-CoV-2.

However, the association between COVID-19 and intense cytokine release 5 patients receiving chimeric antigen receptor T-cell therapy due to innate immune activation by SARS-COV-2. 6, 7 M a n u s c r i p t Compared to COVID-19 patients without cancer, those with cancer appeared to have an increased risk for severe outcomes including intubation and death after adjusting for other COVID-19 risk factors. A case-control study from China of 232 cancer patients with COVID-19 propensity score matched to non-cancer patients by age, sex, and comorbidities found that patients with cancer were more likely to develop severe COVID-19 (OR 3.61). 13 Another smaller study from China 10 also that found that patients with malignancy had a statistically increased odds of intensive care unit (ICU) admission (OR 3.13) and mechanical ventilation (OR 2.71) after adjusting for sex and comorbidities. A case-control study of 218 New York cancer patients with COVID-19 reported an increased odds of death compared to age and sex-matched controls (OR 2.45, p<0.01) with a CFR of 28%. 11 Subgroups of cancer patients who experienced disproportionately high mortality from COVID-19 included those with lung cancer (CFR 18-55%) and hematologic malignancy (CFR 33-41%). 11, 15, 18 Recent active therapy for cancer, 14, 18, 19 including immunotherapy and tyrosine kinase inhibitors, 10 was associated with worse outcomes. Additionally, individuals with cancer made up a larger proportion of COVID-19 patients in both the U.S. (6%) 17 and China (1%) 14 A c c e p t e d M a n u s c r i p t

Focused literature specific to COVID-19 among hematologic malignancy (HM) patients is accumulating rapidly. The largest case series include over 10 patients from the U.K., 23 France, 24 Spain, 25 and China 26 ( Table 1 ).

An earlier study of 28 hematologic malignancy patients from Wuhan, China found that 10%

were positive for COVID-19, among whom the CFR was 62%. 26 A c c e p t e d M a n u s c r i p t

Existing literature on COVID-19 among SOT recipients consists of case series, case reports, and surveys from China, Spain, Italy, Netherlands, Iran, and the U.S ( Table 2) .

Examining the larger studies including more than 10 patients each, 34-52 SOT recipients with COVID-19 were predominantly male and older (median age 51-72 years) than the overall population of COVID-19 patients. 53 Comorbidities including hypertension, diabetes, cardiovascular disease, chronic kidney disease, and obesity were highly prevalent. Common presenting symptoms were fever, dry cough, and diarrhea, with most patients exhibiting lymphopenia and elevated CRP on presentation. Rates of complications including mechanical ventilation were high in most reports, including as high as 39% in a New York City study 35 and 75% in an Iran study, 44 both of kidney transplant recipients. Mortality among SOT recipients ranged significantly from 5-67%, potentially reflecting geographical differences in case number and available hospital resources. The largest study of 90 SOT recipients (kidney, lung, liver, heart, heartkidney) from New York City reported a mortality rate of 18%. 45 Although therapies for COVID-19 among SOT recipients varied significantly by study, decreased immunosuppression was a mainstay of treatment (range 43-100%). The majority of patients in these studies (up to 90%) had antimetabolite therapy held and a smaller proportion had calcineurin inhibitor held or decreased (up 70%). Other therapies varied significantly by center and country and included hydroxychloroquine, tocilizumab, boosted protease inhibitors and intravenous immunoglobulin.

Among the smaller case series and individual case reports of COVID-19 in SOT recipients, notable findings included SOT recipients early in their post-transplant course who had A c c e p t e d M a n u s c r i p t favorable outcomes. 54-57 In a small series of six patients from Italy, the three patients who died were over 10 years from transplant whereas the others who had mild disease were less than two years post-transplant. 56 However, a subsequent study documented that patients early in the post-transplant period accounted for a significant proportion (44%) of deaths among liver transplant recipients with COVID-19. 48 In addition to the significant variability in treatment, some patients who received boosted protease inhibitors experienced significant drug-drug interactions and toxicity. 58,59 Case series of up to six transplant recipients also document a favorable response among kidney transplant recipients with COVID-19 to tocilizumab. 60 While most cases of COVID-19 among SOT recipients were managed with immunosuppression reduction per above, there were several reports describing cases where immunosuppression was maintained and patients recovered. [61] [62] [63] Of note, there have been case reports of HIV transplant patients with COVID-19. The first was of an HIV-positive kidney transplant recipient (CD4 395 cells/µL) with COVID-19 who had a mild course and did not require hospitalization. 64 Another patient with HIV (CD4 820 cells/µL) and liver transplant for hepatitis C cirrhosis was hospitalized for 5 days and required supplemental oxygen via nasal cannula, after which he made a full recovery. 65 While there is significant heterogeneity among studies, many suggest increased disease severity and mortality among SOT recipients with COVID-19. The optimal management of these patients, including changes to immunosuppressive regimens and targeted antiviral therapy, remains unknown. M a n u s c r i p t

Patients with various rheumatologic, dermatologic, neurologic, and gastrointestinal diseases take biologic therapies or targeted disease modifying anti-rheumatic drugs (e.g., Janus kinase (JAK) inhibitors) for immunosuppression. There have been many case reports and case series of COVID-19 in patients taking these medications (mainly biologics) for immunosuppression ( Table 3) .

There have been three case series of COVID-19 in patients with inflammatory bowel disease (IBD), including a case series of 15 patients from Italy and France, 66 12 patients from Spain, 67 and 79 patients from Italy. 68 In total, 64/106 (60%) were taking biologics (anti-TNF inhibitors, vedolizumab, or ustekinumab), symptoms were typical for COVID-19, and the incidence was similar to that in the community. There were only eight deaths, of which only one patient was taking a biologic. In the largest case series, 68 active IBD, age, and comorbidities were associated with worse outcomes, but use of biologic therapies was not. Similarly, a case-control study from Boston compared 52 COVID-19 patients with rheumatologic disease (31% on biologics, 6% JAK inhibitors) to 104 comparators and found no difference in presenting symptoms, rate of hospitalization, or mortality although they did find that patients with rheumatologic disease had a higher risk of requiring ICU admission and mechanical ventilation. 77 There are also case reports of mild COVID-19 in patients taking an anti-TNF 78 and inhibitors of IL-1 79 and IL-6. 80

The Global Rheumatology Alliance recently released its report of 600 COVID-19 patients with underlying rheumatologic disease (39% taking biologics or JAK inhibitors) 81 46% of the patients were hospitalized and 9% died. Notably, monotherapy with a biologic or JAK inhibitor was associated with a lower odds of hospitalization (OR 0.46), largely driven by anti-TNF therapies.

A c c e p t e d M a n u s c r i p t

There are multiple reports of asymptomatic or mild COVID-19 in patients taking dupilumab (IL-4/IL-13 inhibitor) for atopic dermatitis 82,83 or chronic sinusitis. 84 In patients with psoriasis, there are several case reports of mild COVID-19 in patients taking ixekizumab (IL-17 inhibitor), 85 guselkumab (IL-23 inhibitor), 86 or ustekinumab (IL-12/IL-23 inhibitor). 87, 88 Similarly, there is a case series of COVID-19 in nine patients with psoriasis on various biologics (4 anti-TNF, 2 ixekizumab, 1 secukinumab, 1 ustekinumab, 1 guselkumab) where only 1 patient on an anti-TNF required hospitalization (and ICU care) and all recovered. 89

There is also a report of a patient taking guselkumab for psoriasis who developed severe disease but recovered. 87

A large case series of 86 patients from New York City with immune-mediated inflammatory disease (43% IBD, 41% rheumatologic disease, 16% psoriasis) and confirmed or highly suspected COVD-19 was recently published. 90 72% of patients were on a biologic or JAK inhibitor, but use of these was not associated with the need for hospitalization for COVID-19.

One patient died and one required ICU care, and neither was on a biologic or JAK inhibitor.

Symptoms were typical of COVID and the rate of hospitalization was similar to that in the general population with COVID-19 in New York City. Similarly, a large population based study in Italy showed that patients taking biologics or JAK inhibitors (for any indication) had a similar risk for hospitalization and death than those in the general population. 91 A c c e p t e d M a n u s c r i p t

There are five reported cases of asymptomatic to mild infection in patients with multiple sclerosis taking ocrelizumab. [92] [93] [94] [95] In addition, a case registry drawn from a pharmaceutical global safety database identified 74 confirmed COVID-19 cases in MS patients taking ocrelizumab: 35% required hospitalization, 7% required ICU care, and there were no deaths (although 35% had unknown outcomes). The data is more mixed with rituximab, however.

There are three reported cases of mild disease in patients taking rituximab for granulomatosis with polyangiitis (GPA) 96 or MS, 95 but there are also reports of severe (but recovered) infection in a patient with GPA 97 as well as a fatal case in a patient taking rituximab for systemic sclerosis. 98 In summary, the existing data do not show an increased risk of severe COVID-19 in patients taking biologic therapies or targeted disease modifying anti-rheumatic drugs. The effect of these medications in modulating the response to COVID-19, and whether they may actually be protective of severe disease, will require additional, more comprehensive studies.

A small case series described seven patients with primary immunodeficiency and COVID-19 (two with agammaglobulinemia, five with common variable immune deficiency (CVID)). 99 This series reported that the patients with CVID had a more severe course (three requiring ICU admission and one death) than those with agammaglobulinemia (who both had mild disease). The authors postulated this may be related to a role of B cells in the pathologic inflammatory response to SARS-CoV-2 since patients with agammaglobulinemia lack B

cells. An additional case report describes a case of severe COVID-19 in a patient with CVID who required mechanical ventilation but fully recovered 100 (Table 4) .

A c c e p t e d M a n u s c r i p t

In addition to immunosuppression, people with HIV (PWH) might be at risk for more severe COVID-19 due to overlapping demographic and medical characteristics that are known risk factors for severe COVID-19 disease -for example, more than half of PWH in the United States are >50 year old and many have comorbidities such as diabetes, hypertension, and cardiovascular disease. 101 On the other hand, HIV might be protective against severe COVID-19 as immunosuppression could help tamper the cytokine storm of COVID-19 and some antiretrovirals may have theoretical activity against SARS-CoV-2. For example, tenofovir has been shown to bind to the SARS-CoV-2 RNA polymerase. 102 Although there was hope that some of the protease inhibitors might have activity against SARS-CoV-2, existing data does not support the efficacy of lopinavir/ritonavir 103 or darunavir. 104 There have been multiple case series from around the world describing the course of COVID-19 disease in PWH [105] [106] [107] [108] [109] [110] [111] [112] [113] [114] [115] [116] (Table 5 ). The majority of these cases were in patients with well controlled HIV; 75-100% of patients in these studies had a CD4 >200 cells/µL and the median CD4 ranged from 305 to 1068 cells/µL. In terms of disease severity, 25 to 100% of patients required hospitalization and 11-56% required ICU care. The percentage of patients who received COVID-specific therapies varied widely between studies, and included antivirals, steroids, interferon, and tocilizumab. The mortality rate ranged between 0 and 28% in most studies, with the exception of a small case series from New York City where 7 of 9 patients with COVID-19 died. 112 In the largest case series from Spain of 51 HIV-infected patients with COVID-19, the clinical, laboratory, and radiologic parameters of COVID-19 in PWH were similar to those seen in the A c c e p t e d M a n u s c r i p t general population. 108 Interestingly, the rate of tenofovir use in PWH diagnosed with COVID-19 was higher than in PWH without COVID-19, suggesting that tenofovir may not be effective for prophylaxis against COVID-19. A c c e p t e d M a n u s c r i p t

The authors have no conflicts of interests to disclose. M a n u s c r i p t 

World Health Organization. WHO statement regarding cluster of pneumonia cases in

An interactive web-based dashboard to track COVID-19 in real time

RNA respiratory viral infections in solid organ transplant recipients: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice

How I treat respiratory viral infections in the setting of intensive chemotherapy or hematopoietic cell transplantation

COVID-19: consider cytokine storm syndromes and immunosuppression

Cytokine release syndrome in severe COVID-19

COVID-19: risk for cytokine targeting in chronic inflammatory diseases?

Clinical Characteristics of Coronavirus Disease 2019 in China

Characteristics of and Important Lessons From the

COVID-19) Outbreak in China: Summary of a Report of

Cases From the Chinese Center for Disease Control and Prevention

Patients with Cancer Appear More Vulnerable to SARS-CoV-2: A Multi-Center Study During the COVID-19 Outbreak

Case Fatality Rate of Cancer Patients with COVID-19 in a New York Hospital System

Clinical characteristics and outcomes of cancer patients with COVID-19

Clinical characteristics and risk factors associated with COVID-19 disease severity in patients with cancer in Wuhan, China: a multicentre, retrospective, cohort study

Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China

SARS-CoV-2 Transmission in Patients With Cancer at a Tertiary Care Hospital in Wuhan, China

Clinical characteristics of COVID-19-infected cancer patients: A retrospective case study in three hospitals within Wuhan, China. Ann Oncol

Do Patients with Cancer Have a Poorer Rheumatol

A possible role for B cells in COVID-19? Lesson from patients with agammaglobulinemia

The clinical observation of a patient with common variable immunodeficiency diagnosed as having coronavirus disease 2019

The Burden of COVID-19 in People Living with HIV: A Syndemic Perspective

Tenofovir against SARS-CoV-2 RNA dependent RNA polymerase (RdRp): A molecular docking study

A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19

Lack of Antiviral Activity of Darunavir against SARS-CoV-2

Darunavir does not prevent SARS-CoV-2 infection in HIV patients

COVID-19 in patients with HIV: clinical case series

COVID-19 pneumonia in patients with HIV -A Case Series

Description of COVID-19 in HIVinfected individuals: a single-centre, prospective cohort. lancet HIV

SARS-CoV-2 coinfected patients in Istanbul, Turkey

Clinical features and outcomes of HIV patients with coronavirus disease 2019

Hospitalized patients with COVID-19 and HIV: a case series

Clinical features and outcome of HIV/SARS-CoV-2 coinfected patients in The Bronx

A Case Series of Five People Living with HIV Hospitalized with COVID-19 in Chicago, Illinois. AIDS Patient Care STDS

COVID-19 in people living with human immunodeficiency virus: a case series of 33 patients. Infection

Clinical characteristics and outcomes in people living with HIV hospitalized for COVID-19

4 Cases: HIV and SARS-CoV-2 Co-infection in patients from Long Island

A Case Series of MGUS and COVID-19

Following-up allogeneic transplantation recipients during the COVID-19 pandemic

COVID-19 in persons with chronic myeloid leukaemia

Multiple myeloma and COVID-19

COVID-19 in persons with multiple sclerosis treated with ocrelizumab -A pharmacovigilance case series

A c c e p t e d M a n u s c r i p t A c c e p t e d M a n u s c r i p t A c c e p t e d M a n u s c r i p t A c c e p t e d M a n u s c r i p t A c c e p t e d M a n u s c r i p t A c c e p t e d M a n u s c r i p t